Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics, Inc. (NASDAQ: PTIX) is a biopharmaceutical company developing neuro-active peptide and related therapeutics for stress-related and central nervous system (CNS) disorders. The PTIX news feed on Stock Titan highlights company announcements that explain how its clinical programs, business transactions, and listing status are evolving over time.
Investors following PTIX news can read detailed updates on the company’s lead peptide candidate, PT00114, including milestones in single ascending dose and multiple-dose Phase 1 studies in healthy volunteers. Recent press releases describe safety, tolerability, and pharmacokinetic findings for PT00114, as well as the company’s plans to use Phase 1 data to support advancement into Phase 2 studies in stress-related and mood disorders such as depression, anxiety, and PTSD.
News coverage also includes pipeline and corporate developments, such as the announced business combination with Phytanix Bio Inc. to form a combined entity called Phytanix, Inc. Company statements outline how this transaction adds preclinical CNS assets, including a potassium channel modulator, cannabinoid-based compounds with composition-of-matter IP, and modified stilbenoid candidates with anticonvulsant activity in preclinical models.
In addition, PTIX news items feature capital markets and regulatory updates, including private placements, warrant exercises, a 1-for-14 reverse stock split intended to address Nasdaq minimum bid price requirements, and Nasdaq notices related to continued listing standards and periodic filing timelines. Legal filings connected to the Phytanix share exchange agreement and other governance matters are also reported through current reports and press releases. By reviewing this news stream, readers can see how Protagenic describes the progress of its CNS-focused pipeline, its financing activities, and its efforts to manage exchange listing and regulatory obligations.
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) announced the pricing of an underwritten public offering of 3,180,000 units at $4.15 each, raising approximately $13.2 million before expenses. Each unit includes one share of common stock and a warrant priced at $4.98, expiring in five years. An additional 477,000 units can be purchased by underwriters within 45 days. The offering concludes on or around April 29, 2021, and trading for shares and warrants on Nasdaq begins April 27, 2021.